Regeneron Pharmaceuticals Inc (REGN) Event June 15, 2022, 20:11 UTC (99% Neutral) REGENERON PHARMACEUTICALS, INC. (REGN) Announces Regulatory Update Full text
Register to leave comments News bot Oct. 2, 2025, 7:35 a.m. 📋 REGENERON PHARMACEUTICALS, INC. (REGN) - Regulatory Update Filing Date: 2022-06-15 Accepted: 2022-06-15 16:11:23 Event Type: Regulatory Update Event Details: Regeneron Pharmaceuticals Inc (REGN) Announces Regulatory Update Regeneron Pharmaceuticals Inc (REGN) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development: 🔬 Clinical Development Pipeline (REGENERON PHARMACEUTICALS, INC.): Product Type Development Stage Therapeutic Area Source cemiplimab+fianlimab DRUG Phase PHASE2 Melanoma BRAF V600E/K Mutated ClinicalTrials.gov Encorafenib + Binimetinib DRUG Phase PHASE2 Melanoma BRAF V600E/K Mutated ClinicalTrials.gov Cemiplimab DRUG Phase PHASE2 Cutaneous Squamous Cell Carcinoma ClinicalTrials.gov Biopsy PROCEDURE Phase PHASE2 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov Questionnaire Administration OTHER Phase PHASE2 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov Positron Emission Tomography PROCEDURE Phase PHASE2 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov Lumbar Puncture PROCEDURE Phase PHASE2 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov Leukapheresis PROCEDURE Phase PHASE2 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov Computed Tomography PROCEDURE Phase PHASE2 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov Chimeric Antigen Receptor T-Cell Therapy BIOLOGICAL Phase PHASE2 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov Bone Marrow Biopsy PROCEDURE Phase PHASE2 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov Bone Marrow Aspiration PROCEDURE Phase PHASE2 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov Biospecimen Collection PROCEDURE Phase PHASE2 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov Odronextamab BIOLOGICAL Phase PHASE2 Recurrent Diffuse Large B-Cell Lymphoma ClinicalTrials.gov Bendamustine DRUG Phase PHASE3 Follicular Lymphoma (FL) ClinicalTrials.gov Prednisone/prednisolone DRUG Phase PHASE3 Follicular Lymphoma (FL) ClinicalTrials.gov Vincristine DRUG Phase PHASE3 Follicular Lymphoma (FL) ClinicalTrials.gov Doxorubicin DRUG Phase PHASE3 Follicular Lymphoma (FL) ClinicalTrials.gov Cyclophosphamide DRUG Phase PHASE3 Follicular Lymphoma (FL) ClinicalTrials.gov Rituximab DRUG Phase PHASE3 Follicular Lymphoma (FL) ClinicalTrials.gov 💼 Business Developments: Partnership: Not availableAcquisition: Not availableLicensing: Not availableRegulatory ApprovalExecutive Changes: Not available Structured Data: Company Name: Regeneron Pharmaceuticals IncCIK: 0000872589Ticker Symbol: REGNPeriod End Date: 2022-06-10Document Type: 8-K
📋 REGENERON PHARMACEUTICALS, INC. (REGN) - Regulatory Update
Filing Date: 2022-06-15
Accepted: 2022-06-15 16:11:23
Event Type: Regulatory Update
Event Details:
🔬 Clinical Development Pipeline (REGENERON PHARMACEUTICALS, INC.):
💼 Business Developments:
Structured Data: